Joe Marion
Berry & Associates (United States)(US)
Publications by Year
Research Areas
Statistical Methods in Clinical Trials, COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Statistical Methods and Inference, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial(2022)395 cited
- → Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection(2022)248 cited
- → High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure(2024)55 cited
- → Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial(2022)51 cited
- → Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease(2023)22 cited
- → The Use of Historical Controls in Clinical Trials(2023)19 cited
- → Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis(2025)12 cited
- → Finite-sample complexity of sequential Monte Carlo estimators(2023)6 cited
- → Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection(2022)5 cited
- → Bayesian model of disease progression in mucopolysaccaridosis IIIA(2022)1 cited